The Democratic Republic of Congo is set to receive 70,000 doses of the Ervebo Ebola vaccine—a crucial step in tackling a deadly Bundibugyo virus outbreak that’s already claimed over 2,400 lives. Though licensed for a different strain, early research hints Ervebo may still offer some protection. Twenty thousand doses will be used in a clinical trial to test its efficacy against this specific virus, while the remaining fifty thousand go to frontline healthcare workers battling the rapidly spreading epidemic. With no approved treatments and cases surging beyond monitored groups, every dose counts in the race to contain this outbreak.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
